Evidence map›Paper›PMID 41355371›Full record

ReviewBrain and behavior2025

Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review.

Natasha Elaine Hastings, Khalil El Abdi, Fazeela Bibi, Bilal Aslam, Milka Rosario Nuñez, Muhammad Tahla Rehman Sherani, Sujeet Shadmani, Umama Alam, Vohra Maham Hassan, Hoor-E-Ainaa and 3 more

Registry-linked trialAbstract readReview
In one paragraph

Review in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07727239 (Efficacy and Safety of Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07727239 narecruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy and Safety of Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1: A Randomised, Double-blind, Sham-Controlled, Single-Centre Trial

TypeinterventionalSponsorXijing HospitalRan2026 to 2027Enrolled24ConditionsNarcolepsy Type 1ArmsActive Temporal Interference Stimulation, Sham Temporal Interference Stimulation
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Natasha Elaine HastingsSchool of Medicine, St. George's University, St. George's, Grenada.
Khalil El AbdiFaculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
Fazeela BibiJinnah Medical and Dental College, Karachi, Pakistan.
Bilal AslamUniversity of Lahore, Lahore, Pakistan.
Milka Rosario NuñezUniversidad Iberoamericana (UNIBE), Santo Domingo, Dominican Republic.
Muhammad Tahla Rehman SheraniArmy Medical College, Rawalpindi, Pakistan.
Sujeet ShadmaniShaheed Mohtarma Benazir Bhutto Medical College, Karachi, Pakistan.
Umama AlamKhyber Medical College, Khyber, Pakistan.
Vohra Maham HassanJinnah Medical and Dental College, Karachi, Pakistan.
Hoor-E-AinaaAyub Medical College, Abbotabad, Pakistan.
Hania ImranWah Medical College, Wah Cantt, Pakistan.
James HannaSchool of Medicine, St. George's University, St. George's, Grenada.
Said Hamid SadatKabul University of Medical Sciences Abu Ali Ibn Sina, Kabul, Afghanistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo critically synthesize the current understanding of narcolepsy's pathophysiology, diagnostic challenges, and treatment landscape, and to articulate the emerging paradigm shift from symptomatic management toward disease modification. DATA SOURCES: This narrative review is based on a strategic search of literature from PubMed and Google Scholar published between 2015 and 2025, focusing on disease mechanisms, diagnosis, and established and emerging therapeutic interventions. SYNTHESIS OF

findingsNarcolepsy is a neurological disorder fundamentally driven by an irreversible loss of hypocretin-producing neurons, a process strongly linked to an autoimmune response in individuals with the HLA-DQB1*0602 allele. Despite this well-defined pathophysiology, diagnosis is often delayed by nearly a decade due to limited physician awareness and symptom overlap with a wide range of psychiatric and metabolic comorbidities. Current pharmacological strategies, while providing partial relief from excessive daytime sleepiness and cataplexy, are purely symptomatic and fail to address the core hypocretin deficiency. The field is now at a critical inflection point, with promising research into hypocretin receptor agonists, targeted immunotherapies, and neuromodulation techniques poised to directly address the underlying pathology. CONCLUSION AND RELEVANCE: The existing therapeutic approach to narcolepsy is palliative, not restorative, leaving a significant unmet need for interventions that can alter the disease's natural history. The future of narcolepsy management depends on translating novel pathophysiological insights into disease-modifying therapies. Achieving this requires a concerted effort to accelerate diagnosis, validate new clinical endpoints, and prioritize the development of interventions capable of restoring neurological function. Such an approach holds the potential to move beyond symptom suppression and fundamentally improve the lives of individuals with narcolepsy.

Indexed as

NarcolepsyHumansOrexinsOrexinscataplexyexcessive daytime sleepinesshypocretinnarcolepsytherapy

Identifiers

PMID41355371
PMCPMC12683072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.